Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists

NCT00607724 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00607724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00607724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2007
Completion date
November 30, 2009
Enrollment
68 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific